This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.
Happy Friday, readers!
I have a selfish request of all of you this evening.
If you have any thoughts about which drugs, medicines, therapies, procedures, etc have served the American (and global) public best over the past decade, I’d love to read what you have to say.
I have a few ideas. Truvada and PrEP (those treatments that can essentially prevent HIV transmission) come to mind. Cancer immunotheraphy, new gene therapies, and so many other drugs are clear contenders.
But I want to hear your expert opinions. I’m sure there are plenty of things I’m missing – a rare disease drug I’ve never heard of, or a therapy for condition I never knew existed. Please weigh in.
Read on for the day’s news, and have a wonderful weekend.
Sy Mukherjee
sayak.mukherjee@fortune.com
@the_sy_guy
DIGITAL HEALTH
ViiV, NIH team up on HIV antibodies. ViiV Healthcare, the joint project between GlaxoSmithKline and Pfizer, is teaming up with the National Institutes of Health to tackle HIV with a new kind of therapy. The experimental "broadly neutralizing antibody" could potentially slash costs (and be an effective medicine against) the HIV-1 strain; there is plenty of work to be done, and the proof is in the pudding. (Endpoints News)
THE BIG PICTURE
Flu season is picking up. Get your shots. Flu season is already upon us, according to the CDC (not exactly surprising given that it can last all the way up to early summer). But it's already hit about 30 states, and it could be a brutal season. As the mantra goes: Get your shots (if not for yourself, at the very least for others). (NBC News)
REQUIRED READING
Vaping Fight Hits Fever Pitch With White House Meeting, by Bloomberg
The 27 Best Stocks to Buy for 2020, by Rey Mashayekhi & Anne Sraders
AT&T Announces Its 5G Rollout, by Aaron Pressman
Sign up for other Fortune newsletters.
IF YOU LIKE THIS EMAIL...
Share today’s Brainstorm Health with a friend.
Did someone share this with you? Sign up here. For previous editions, click here.
For even more, check out raceAhead, Fortune's daily newsletter on culture in corporate America. Sign up here.
